Nina Steele

Assistant Professor

University of Cincinnati
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (23)

Identifying spatially variable genes (SVGs) has been an essential task in spatial transcriptomics. In addition to SVGs detection, there are genes exhibiting expression patterns that are associated with cellular developmental stages or lineage fates across a tissue section. Identifying such genes could provide novel insights into tumor metastasis. Here, we introduce a unified statistical model, termed TrajEctory-preServed and SpAtially-variable gene detection (TESSA), to detect both types of genes. Moreover, we propose a novel strategy to address the inherent double-dipping issue commonly encountered when assessing temporal gene effects in transcriptomics analysis. We demonstrate the testing performance through extensive simulation studies and real applications to several publicly available datasets. Downstream analyses further highlight the potential of our method in identifying genes associated with tumor progression and enhancing spatial domain detection.

Year:

2025

Supplementary Figure S4. CK5 and CK17 do not predict treatment response or time to recurrence. A) Combining CK5 and GATA6 IHC does not predict overall survival. B) CK17 high, GATA6 low tumors display improved survival compared to CK17 low, GATA6 high tumors. C) Kaplan-Meier survival curves for CK5 positive and negative tumors treated with first-line gemcitabine chemotherapy. D) Kaplan-Meier survival curves for CK17 positive and negative tumors treated with first-line gemcitabine chemotherapy. E) CK5 status does not predict time to recurrence. F) CK17 positive tumors show longer time to recurrence than CK17 negative tumors, the opposite phenotype expected from the basal subtype.

Year:

2025

Supplementary Figure S6. GATA6 expression predicts chemotherapy response to GnP but not mFFX. A) GATA6low metastatic tumors have significantly worse overall survival when treated with combination GnP first-line chemotherapy. B) GATA6 status does not predict overall survival when patients receive first line mFFX chemotherapy.

Year:

2025

Supplementary Figure S3. Consort Diagram and Mixed Populations. A) Consort diagram of analyzed samples. For survival analyses, all patients with intact cores (n = 491) were assessed. For treatment response analyses, patients were further subdivided by type of chemotherapy received, and neoadjuvant-treated samples were considered separately (n = 51). B) Mixed (HMGA2+ GATA6+) and double negative (HMGA2- GATA6-) populations show intermediate survival between basal and classical tumors.

Year:

2025

Supplementary Figure S2. Demographic data for analyzed cohort. A) Age distribution for TMA and Ochsner cohorts. B) Race distribution for TMA and Ochsner cohorts. C) Proportions of disease by stage (left) and resulting survival (right) predicts survival in TMA cohort (AJCC 8th edition).

Year:

2025

Supplementary Figure S6. GATA6 expression predicts chemotherapy response to GnP but not mFFX. A) GATA6low metastatic tumors have significantly worse overall survival when treated with combination GnP first-line chemotherapy. B) GATA6 status does not predict overall survival when patients receive first line mFFX chemotherapy.

Year:

2025

Supplementary Figure S3. Consort Diagram and Mixed Populations. A) Consort diagram of analyzed samples. For survival analyses, all patients with intact cores (n = 491) were assessed. For treatment response analyses, patients were further subdivided by type of chemotherapy received, and neoadjuvant-treated samples were considered separately (n = 51). B) Mixed (HMGA2+ GATA6+) and double negative (HMGA2- GATA6-) populations show intermediate survival between basal and classical tumors.

Year:

2025

Supplementary Figure S4. CK5 and CK17 do not predict treatment response or time to recurrence. A) Combining CK5 and GATA6 IHC does not predict overall survival. B) CK17 high, GATA6 low tumors display improved survival compared to CK17 low, GATA6 high tumors. C) Kaplan-Meier survival curves for CK5 positive and negative tumors treated with first-line gemcitabine chemotherapy. D) Kaplan-Meier survival curves for CK17 positive and negative tumors treated with first-line gemcitabine chemotherapy. E) CK5 status does not predict time to recurrence. F) CK17 positive tumors show longer time to recurrence than CK17 negative tumors, the opposite phenotype expected from the basal subtype.

Year:

2025

Supplementary Figure S2. Demographic data for analyzed cohort. A) Age distribution for TMA and Ochsner cohorts. B) Race distribution for TMA and Ochsner cohorts. C) Proportions of disease by stage (left) and resulting survival (right) predicts survival in TMA cohort (AJCC 8th edition).

Year:

2025

Purpose: The purpose of this study was to establish HMGA2 as a marker of basal-like disease in pancreatic ductal adenocarcinoma (PDAC) and explore its use as a biomarker for prognosis and treatment resistance. Experimental Design: We identified high-mobility group A2 (HMGA2) protein expression in basal PDAC cells in a single-cell RNA sequencing (RNA-seq) atlas of 172 patient samples. We then analyzed HMGA2 expression, along with expression of the classic marker GATA-binding factor 6 (GATA6), in a cohort of 580 PDAC samples with multiplex IHC. We further supplemented these data with an additional 30 diverse patient samples and multiple independent single-cell RNA-seq databases. Results: We found that expression of HMGA2, but not previously described basal markers cytokeratins 5 or 17, predicted overall survival in our cohort. Combining HMGA2 and GATA6 statuses allowed for the identification of two key study groups: an HMGA2+/GATA6− cohort with worse survival, low tumor-infiltrating CD8 + T cells, increased FAP+ fibroblasts, and poorer response to gemcitabine-based chemotherapies ( n = 94, median survival = 11.2 months after surgery) and an HMGA2−/GATA6+ cohort with improved survival, increased CD8 + T-cell infiltrate, decreased FAP+ fibroblasts, and improved survival with gemcitabine-based chemotherapy ( n = 198, median survival = 21.7 months after surgery). HMGA2 was also prognostic for overall survival in RNA-seq from an independent cohort. Conclusions: IHC stratification of primary tumors by HMGA2 and GATA6 statuses in pancreatic cancer is associated with differential outcomes, survival following chemotherapy, and tumor microenvironments. As a nuclear marker for basal disease, HMGA2 complements GATA6 to identify disease subtypes in PDAC.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (34)

Janusz Franco-Barraza

Assistant Research Professor

Fox Chase Cancer Center

UNITED STATES
View details

Jonathan Preall

Research Associate Professor

Cold Spring Harbor Laboratory

UNITED STATES
View details

Michael Feigin

Assistant Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Yuehua Cui

Michigan State University

UNITED STATES
View details

Rachael Safyan

Assistant Professor

University of Washington

UNITED STATES
View details

Rosalie C. Sears

Professor; Co-Director Brenden Colson Center for Pancreatic Care

Oregon Health & Science University

UNITED STATES
View details

Howard Crawford

Professor

University of Michigan

UNITED STATES
View details

Allison R. Schulman

University of Michigan

UNITED STATES
View details

Pierre A. Coulombe

G. Carl Huber Professor and Chair

University of Michigan

UNITED STATES
View details

Jorge Machicado

Assistant Professor

University of Michigan

UNITED STATES
View details

Marina Pasca Di Magliano

Associate Professor

University of Michigan

UNITED STATES
View details

yuesong wu

Michigan State University

UNITED STATES
View details

Yuying Xie

Associate Professor

Michigan State University

UNITED STATES
View details

Sita Kugel

Professor

Fred Hutch Cancer Center

UNITED STATES
View details

David G. DeNardo

Professor of Medicine

Washington University School of Medicine

UNITED STATES
View details

Ling Huang

Assistant Professor

Michigan State University

UNITED STATES
View details

Vaibhav Sahai

University of Michigan

UNITED STATES
View details

Sunil Hingorani

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

E. Gabriela Chiorean

Professor of Medicine

University of Washington

UNITED STATES
View details

Jiaqi Shi

Professor

University of Michigan

UNITED STATES
View details

Abdulrahman Alahmari

Assistant professor

prince sattam bin abdulaziz university

SAUDI ARABIA
View details

Filip Bednar

University of Michigan

UNITED STATES
View details

Kiran Vij

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Craig Galban

Professor

University of Michigan

UNITED STATES
View details

Ryan C. Fields

University of Rochester

UNITED STATES
View details

Kathleen DelGiorno

Assistant Professor

Vanderbilt University

UNITED STATES
View details

Timothy Frankel

Assistant Professor

University of Michigan Hospital

UNITED STATES
View details

Mukund Seshadri

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Yaqing Zhang

Associate Professor

University of Michigan

UNITED STATES
View details

Rosa Menjivar

University of California, San Francisco

UNITED STATES
View details

Christos Fountzilas

Associate Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

William Burns

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Mark D. Parker

Associate Professor

University at Buffalo

UNITED STATES
View details

Stefanie Galban

-

UNITED STATES
View details